We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Research Suggests A Better Approach to Breast Cancer Screening

By HospiMedica International staff writers
Posted on 14 Jun 2016
Researchers are unhappy with current models for determining mammography screening risk/benefit ratios, and suggest that the measurement of Quality-Adjusted Life-Years (QALYs) gained, when breast cancer is prevented, could be more accurate.

Researchers in Norway found that there were large uncertainties in the evaluation a long running breast cancer screening program in the country, especially in the estimates of over-diagnoses.

The researchers from the Department of Screening at the Cancer Registry of Norway (Oslo, Norway) studied the benefit/detriment ratio estimates of the Norwegian Breast Cancer Screening Program (NBCSP) in 2015, and presented the results at the annual meeting of the Radiological Society of North America (RSNA 2015). More...
The results were published in the March 2016, issue of the Journal of Medical Screening. Under the program, all women aged 50 to 69 receive an invitation for screening every two years. The Research Council of Norway also evaluated the screening program between 2007 and 2015.

According to the researchers, the range of estimates varies widely and needs to be interpreted carefully before publication. In addition the estimates include two different variables that are not comparable — lives saved and cases of over-diagnosis. The researchers found that the program saved about one life per 1-2 women with epidemiologic over-diagnosis. The researchers suggest that using a simple risk/benefit ratio could be misleading. Instead, they propose the use of Quality-Adjusted Life-Years (QALYs) gained when breast cancer is prevented, compared to QALYs lost in cases of over diagnosis.

Norway’s health minister decided to continue the NBCSP program without changes despite the findings of the researchers.

Solveig Hofvind, PhD, researcher, Department of Screening, Cancer Registry of Norway, said, “Our research demonstrates that it’s very difficult to find clear numbers to show the risk/benefit ratio of mammography screening. The range is so wide and it depends on so many different factors, that it’s important to understand the screening logistics and the epidemiology in order to choose the right model to estimate such a ratio. In any event, if a patient asks for information about risk/benefit ratios, that information should be shared and interpreted with substantial. I know women may ask about this ratio and we have to be prepared to give them information with the best knowledge we have today.”

Related Links:
Cancer Registry of Norway


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Medical-Grade Display
HL2316SHTB
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.